Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene
- PMID: 1923504
Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene
Abstract
Mutations in the p53 gene are associated with a wide variety of human tumors, including those of the breast. To assess functionally the role of the p53 gene in the development of human breast cancer, we introduced either wild-type or mutant p53 cDNA into three human breast cancer cell lines by DNA transfection. The cell lines MDA-MB 468 and T47 D contain only single mutated copies of the p53 gene, whereas the status of p53 in the breast cancer cell line MCF 7 remains equivocal. Following transfection, MCF 7 cells continued to grow unaffected both in vitro and in vivo in the presence of high levels of expression of the exogenous wild-type p53 gene. In contrast, however, the continued expression of an exogenous wild-type p53 gene was incompatible with cellular growth in both the MDA-MB 468 and T47 D cell lines. Elevated levels of expression of the exogenous mutant p53 gene did not alter the growth of the cell lines in vitro. These data strongly suggest that the wild-type p53 gene can function as a suppressor of cellular growth in breast cancer cells. That the wild-type p53 gene does not suppress the growth of MCF 7 cells indicates that at least some human breast tumors can arise without functional inactivation of the p53 gene by mutation. These tumors may represent a separate prognostic group.
Similar articles
-
Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions.Cancer Res. 1994 Apr 1;54(7):1818-24. Cancer Res. 1994. PMID: 8137297
-
p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):173-82. doi: 10.1016/j.jsbmb.2004.12.011. Epub 2005 Jan 28. J Steroid Biochem Mol Biol. 2005. PMID: 15860260
-
Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.Cancer Res. 1991 Sep 1;51(17):4716-20. Cancer Res. 1991. PMID: 1873816
-
Friend virus induced murine erythroleukaemia: the p53 locus.Cancer Surv. 1992;12:137-51. Cancer Surv. 1992. PMID: 1638545 Review.
-
p53 as a mutagen test in breast cancer.Environ Mol Mutagen. 2002;39(2-3):216-27. doi: 10.1002/em.10065. Environ Mol Mutagen. 2002. PMID: 11921192 Review.
Cited by
-
Anticancer activity of a sub-fraction of dichloromethane extract of Strobilanthes crispus on human breast and prostate cancer cells in vitro.BMC Complement Altern Med. 2010 Aug 5;10:42. doi: 10.1186/1472-6882-10-42. BMC Complement Altern Med. 2010. PMID: 20684795 Free PMC article.
-
TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro.Avicenna J Med Biotechnol. 2015 Apr-Jun;7(2):76-9. Avicenna J Med Biotechnol. 2015. PMID: 26140185 Free PMC article.
-
Pericellular oxygen depletion during ordinary tissue culturing, measured with oxygen microsensors.Cell Prolif. 2005 Aug;38(4):257-67. doi: 10.1111/j.1365-2184.2005.00345.x. Cell Prolif. 2005. PMID: 16098184 Free PMC article.
-
Cancer risks from germline p53 mutations.J Clin Invest. 1992 Nov;90(5):1637-41. doi: 10.1172/JCI116034. J Clin Invest. 1992. PMID: 1430194 Free PMC article. Review. No abstract available.
-
MicroRNA-16 sensitizes drug-resistant breast cancer cells to Adriamycin by targeting Wip1 and Bcl-2.Oncol Lett. 2019 Sep;18(3):2897-2906. doi: 10.3892/ol.2019.10637. Epub 2019 Jul 18. Oncol Lett. 2019. PMID: 31452770 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous